




# PHARMACEUTICAL 2019

Propanc Biopharma Inc.  
Rank 358 of 363





# PHARMACEUTICAL 2019

Propanc Biopharma Inc.  
Rank 358 of 363

The relative strengths and weaknesses of Propanc Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Propanc Biopharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 658% points. The greatest weakness of Propanc Biopharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 347% points.

The company's Economic Capital Ratio, given in the ranking table, is -534%, being 571% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	61
Cost of Goods Sold	31
Intangible Assets	0
Liabilities, Current	6,823
Liabilities, Non-Current	0
Other Assets	2.2
Other Compr. Net Income	500
Other Expenses	-179
Other Liabilities	0
Other Net Income	-3,259
Other Revenues	0
Property and Equipment	8.3
Research and Development	1,826
Selling, General and Administrative Expense	2,104

Output Variable	Value in 1000 USD
Assets	71
Liabilities	6,823
Expenses	3,781
Revenues	0
Stockholders Equity	-6,752
Net Income	-7,039
Comprehensive Net Income	-6,789
Economic Capital Ratio	-534%